Conference Track

Myelodysplastic Syndromes

Source: CCO Independent Conference Coverage of the American Society of Hematology 2007 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Azacitidine Schedules Without Weekend Administration Appear Safe and Effective in MDS
Single-Agent Lenalidomide Active in Patients With Higher-Risk MDS and Del(5q) but Associated With Considerable Toxicity
Low-Dose Decitabine Yields Promising Results in Patients With Intermediate-Risk, High-Risk, or Noncategorized MDS
Iron Chelation Therapy Improves Overall Survival in Patients With Transfusion-Dependent Low-Risk or Intermediate-1–Risk MDS
Deferasirox Safely and Effectively Reduces Iron Overload in Patients With MDS
Ribosomal Protein Gene Loss Identified as Cause of 5q- Syndrome
Oral Formulation of Novel Glutathione Analogue TLK199 Safe and Effective in Patients With MDS
Proteins Involved in Cell Cycle Progression Identified as Molecular Targets of Lenalidomide
Romiplostim (AMG 531) Produces Sustained Increase in Platelets for Patients With MDS and Severe Thrombocytopenia
Azacitidine Highly Active as First-Line Treatment for Patients With Higher-Risk MDS
Lenalidomide-Associated Cytopenias Independently Predict for Transfusion Independence Among Patients With Lower-Risk MDS With Del(5q)

Expert Analysis

Myelodysplastic Syndromes

Program Director: Roy A. Beveridge, MD

Faculty:

Alan F. List, MD
Azra Raza, MD
Lewis Silverman, MD

Moderator: Allen S. Yang, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe key studies of hypomethylating agents for the treatment of myelodysplastic syndromes
Explain the significance of the deletion 5q syndrome and the impact it has on treatment choices
Discuss the role of iron chelation in the treatment of patients with transfusion-dependent myelodysplastic syndromes
Review studies of novel therapeutics for treatment and supportive care of myelodysplastic syndromes
Identify candidate genes involved in the pathogenesis of 5q- syndrome

CME CREDIT INFORMATION

Release Date: 02/22/08

Expiration Date: 02/21/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing CE credits

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.